Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Androgen replacement therapy

C Wang1, R S Swerdloff

  • 1Department of Medicine, Harbor-UCLA Medical Center, Torrance, California 90509-2910, USA. wang@harbor6.humc.edu

Annals of Medicine
|February 7, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The platelet-derived growth factor alpha-receptor is encoded by a growth-arrest-specific (gas) gene.

Proceedings of the National Academy of Sciences of the United States of America·1996
Same author

Data from men in greater Seattle area reveals no downward trend in semen quality: further evidence that deterioration of semen quality is not geographically uniform.

Fertility and sterility·1996
Same author

Microsatellite instability in transitional cell carcinoma of the urinary tract and its relationship to clinicopathological variables and smoking.

International journal of cancer·1996
Same author

Sexual dimorphism of cardiovascular responses to early blockade of bradykinin receptors.

Hypertension (Dallas, Tex. : 1979)·1996
Same author

Rate-determining steps for tyrosine phosphorylation by the kinase domain of v-fps.

Biochemistry·1996
Same author

Cell-type-specific expression of the platelet-derived growth factor alpha receptor: a role for GATA-binding protein.

Molecular and cellular biology·1996

Androgen therapy is mainly for hypogonadal men but is being studied for older men, contraception, and postmenopausal women. Benefits must be weighed against risks for non-hypogonadal uses.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Androgen therapy is established for symptomatic hypogonadal men.
  • Investigational uses include older men, muscle wasting, male contraception, and adjuncts to hormone therapy in postmenopausal women.

Purpose of the Study:

  • To review current and emerging applications of androgen therapy.
  • To discuss the development of novel androgen formulations.
  • To highlight the importance of risk-benefit assessment for non-traditional indications.

Main Methods:

  • Literature review of clinical investigations and pharmaceutical developments in androgen therapy.
  • Analysis of potential benefits and risks across different patient populations.

Main Results:

Related Experiment Videos

  • New long-acting injectable, transdermal, and sublingual androgen preparations are under development.
  • Androgen therapy is being explored for age-related testosterone decline, muscle wasting, male contraception, and in women.

    • Conclusions:

    • The use of androgens beyond male hypogonadism requires careful consideration of potential risks versus benefits.
    • Future research may lead to "designer androgens" with targeted effects and reduced side effects.